Aglycosylated antibodies and the methods of making and using them: WO2008030564

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 1, 2009, Pages 101-105

  Jefferis, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Aglycosylated IgG; IgG; Oligosaccharides; Recombinant antibody

Indexed keywords

IMMUNOGLOBULIN G1; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; WO 2008030564;

ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; DEGLYCOSYLATION; DRUG STRUCTURE; GENETIC HETEROGENEITY; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW;

ANTIBODIES, MONOCLONAL; DRUG DESIGN; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; OLIGOSACCHARIDES; PATENTS AS TOPIC; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 67649413244     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770802592408     Document Type: Review

References (16)

1. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357.
2. Moutel S, Perez F. "Antibodies-Europe. Engineering the next generation of antibodies". Biotechnol J 2008;3:298-300
3. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007;6:349-356 (Pubitemid 46696550)
4. Jefferis R. Glycosylation of Recombinant Antibody Therapeutics. Biotechnol Prog 2005;21:11-16 (Pubitemid 40218466)
5. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007;7:1401-1413 (Pubitemid 47475656)
6. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007;12:898-910 (Pubitemid 350052671)
7. Sinclair AM, Elliott SJ. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. Pharm Sci 2005;94:626-1635 (Pubitemid 41360859)
8. Shields RL, et al. Lack of Fucose on Human IgG1 N-Linked oligosaccharide improves binding to human FcγRIII and Antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-26740 (Pubitemid 34951677)
9. Shinkawa T, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-3473 (Pubitemid 36801263)
10. Niwa R, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005;306:151-160 (Pubitemid 41739846)
11. Ferrara C, et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 2006;93:851-861
12. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004;4:89-99 (Pubitemid 38209203)
13. Nezlin R, Ghetie V. Interactions of immunoglobulins outside the antigen-combining site. Adv Immunol 2004;82:155-215 (Pubitemid 38209511)
14. Krapp S, et al. Structural analysis of human IgG glycoforms reveals a correlation between oligosaccharide content, structural integrity and Fcγ-receptor affi nity. J Mol Biol 2003;325:979-989 (Pubitemid 36263407)
15. Shields RL, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2002;276:6591-6604
16. Oganesyan V, et al. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 2008;45:1872-1882